DefinitionThis section has been translated automatically.
Dual, specific, selective inhibitor (4-azosteroid) of the enzymes 5-α reductase type I and type II.
Pharmacodynamics (Effect)This section has been translated automatically.
- Reduction of the plasma levels of dihydrotestosterone and in the prostate by 80-90% (dose-dependent) within 1-2 weeks, after 1-2 years of therapy by more than 90%. Serum testosterone levels rise slightly (by about 20%). Reduction of the PSA in the serum by about 50%.
- According to approval studies, dutasteride stabilizes the process of androgenetic alopecia in men and may induce the growth of new hair. An efficacy in bitemporal receding of the hairline ("receding hairline") or in end-stage hair loss has not been investigated in registration studies and is therefore not proven.
You might also be interested in
IndicationThis section has been translated automatically.
Benign prostatic hyperplasia (BPH). Alopecia androgenetica in men ( off-label use).
Pregnancy/nursing periodThis section has been translated automatically.
Contraindicated during pregnancy.
Remember! Dutasteride, if taken by a pregnant woman, can cause malformations of the external genitals of male fetuses!
Dosage and method of useThis section has been translated automatically.
Adults: once/day 0.5 mg p.o.
Undesirable effectsThis section has been translated automatically.
Impotence (5-6% of patients), reduced libido (3% of patients), ejaculation disorders (1-2% of patients), gynecomastia or painful sensitivity to pressure in the breast (approx. 1% of patients).
InteractionsThis section has been translated automatically.
Increase of plasma levels of dutasteride by CYP3A4 inhibitors such as ritonavir, indinavir, nefazodone, itraconazole, ketoconazole.
ContraindicationThis section has been translated automatically.
Use in women, children, adolescents and patients with severe liver dysfunction. Hypersensitivity to dutasteride or other 5-α reductase inhibitors.
PreparationsThis section has been translated automatically.
Avodart
LiteratureThis section has been translated automatically.
- Barkin J et al (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 44: 461-466
- Evans HC et al (2003) Dutasteride. Drugs Aging 20: 905-916
- Munster U et al (2003) Testosterone metabolism in human skin cells in vitro and its interaction with estradiol and dutasteride. Skin Pharmacol Appl Skin Physiol 16: 356-366
Prof. Dr. med. Peter Altmeyer